Oncolytics Biotech (OTCMKTS:ONCYF) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.
Separately, Zacks Investment Research downgraded shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Friday, August 11th.
Shares of Oncolytics Biotech (OTCMKTS ONCYF) traded down $0.01 during midday trading on Friday, hitting $0.53. 46,491 shares of the company’s stock were exchanged, compared to its average volume of 192,394. Oncolytics Biotech has a fifty-two week low of $0.14 and a fifty-two week high of $0.85.
Oncolytics Biotech Inc is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Oncolytics Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.